CytomX Therapeutics (CTMX) Debt Ratio (2014 - 2015)
CytomX Therapeutics (CTMX) posted Debt Ratio of 0.0 for Q4 2015, down 99.03% on a QoQ basis from 0.04 in Q4 2014, and down 99.03% year-over-year from 0.04 in Q4 2014.
CytomX Therapeutics (CTMX) Debt Ratio (2014 - 2015) Analysis & Trends
CytomX Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q4 2015.
- Quarterly Debt Ratio fell 99.03% year-over-year to 0.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was 0.0 (down 99.03% YoY) and the FY2015 annual result came in at 0.0, down 99.03% from the prior year.
- Debt Ratio was 0.0 for Q4 2015 at CytomX Therapeutics, down from 0.04 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.04 in Q4 2014 and bottomed at 0.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 0.00 |
| Dec 31, 2014 | 0.04 |